NTRK fusion ‘pan-tumour’ drug approval marks new approach to cancer treatment

The Australian registration of a ‘pan-tumour’ TRK inhibitor to treat patients with a wide range of NTRK fusion-positive cancers signals a new approach to cancer treatment that will become increasingly common, a genomic expert says. Professor David Thomas, Head of the Genomic Cancer Medicine Laboratory at the Garvan Institute of Medical Research in Sydney, told ...

Already a member?

Login to keep reading.

© 2021 the limbic